Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
Study Information
Alliance Study ID: A091202
NCT Study ID (ClinicalTrials.gov): NCT02249949
Alliance Committee: Experimental Therapeutics
Disease or Cancer Type: Sarcoma & Soft Tissue / Bone Cancers
Alliance Study Chair: Michael Pishvaian, MD, PhD
Status: COMPLETED
Study Description
This phase II trial studies how well efatutazone dihydrochloride works in treating patients with previously treated myxoid liposarcoma that cannot be removed by surgery. Drugs used in chemotherapy, such as efatutazone dihydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information